Dual-targeting nanotherapeutics antagonize hyperinsulinemia-promoted tumor growth via activating cell autophagy-Reference-Cited by-同舟云学术

Dual-targeting nanotherapeutics antagonize hyperinsulinemia-promoted tumor growth via activating cell autophagy

Published:2019 Issue:43 Volume:7 Page:6751-6758
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Huang Jiarun¹²³⁴,Liu Yuedan¹²³⁴,Liu Ting¹²³⁴,Chang Yanzhou¹²³⁴,Chen Tianfeng¹²³⁴^ORCID,Li Xiaoling⁵²³⁴

Affiliation:

1. The First Affiliated Hospital, and Department of Chemistry

2. Jinan University

3. Guangzhou 510632

4. China

5. Institute of Food Safety and Nutrition

Abstract

Herein, a dual-targeting selenium nanotherapeutics has been designed and proposed as a tumor therapy drug to antagonize high insulin. This study provides a new strategy for Se-based nanotherapeutics in tumor therapy under hyperinsulinemia conditions.

Funder

National Natural Science Foundation of China

National Key Scientific Instrument and Equipment Development Projects of China

Natural Science Foundation of Guangdong Province

China Postdoctoral Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2019/TB/C9TB01197H

Reference43 articles.